Completed PHASE3 INTERVENTIONAL 2-arm NCT00424463

Expanded Controlled Study of Safety and Efficacy of MCI-186 in Patients With Amyotrophic Lateral Sclerosis (ALS)

An Expanded Controlled Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis in Double-Blind, Parallel-Group, Placebo-Controlled Manner (Phase 3)

Sponsor: Tanabe Pharma Corporation

Conditions Amyotrophic Lateral Sclerosis (ALS)

Interventions MCI-186 Placebo of MCI-186

Updated 10 times since 2017 Last updated: Dec 15, 2025 Started: Jan 31, 2007 Primary completion: May 31, 2009 Completion: May 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00424463, this PHASE3 trial focuses on Amyotrophic Lateral Sclerosis (ALS) and remains completed. Sponsored by Tanabe Pharma Corporation, it has been updated 10 times since 2007, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

10 versions recorded

Feb 2026 — Present [monthly]

Completed PHASE3
Jan 2026 — Feb 2026 [monthly]

Completed PHASE3
Sep 2024 — Jan 2026 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3

▶ Show 5 earlier versions

Sep 2018 — Jan 2021 [monthly]

Completed PHASE3
Aug 2018 — Sep 2018 [monthly]

Completed PHASE3
Jul 2018 — Aug 2018 [monthly]

Completed PHASE3
Jun 2018 — Jul 2018 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Jan 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Tanabe Pharma Corporation

Data source: Tanabe Pharma Corporation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Watari-gun, Japan